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ABSTRACT
It is estimated that 75% of all women will experience at least 1 episode of vulvovaginal candidiasis
(VVC) during their lifetimes. Most patients with acute VVC can be treated with short-term regi-
mens that optimize compliance. Since current topical and oral antifungals have shown comparably
high efficacy rates, other issues should be considered in determining the most appropriate therapy. It
is possible that the use of short-duration narrow-spectrum agents may increase selection of more
resistant organisms which will result in an increase of recurrent VVC (RVVC). Women who are
known or suspected to be pregnant and women of childbearing age who are not using a reliable
means of contraception should receive topical therapy, as should those who are breast-feeding or
receiving drugs that can interact with an oral azole and those who have previously experienced
adverse effects during azole therapy. Because of the potential risks associated with systemic treat-
ment, topical therapy with a broad-spectrum agent should be the method of choice for VVC,
whereas systemic therapy should be reserved for eitherRVVC or cases where the benefits outweigh
any possible adverse reactions. (C) 1994 Wiley-Liss, Inc.
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ulvovaginal candidiasis (VVC) remains, after
bacterial vaginosis, the most common vaginal
infection in the United States.
1,2 Researchers esti-
mate that 75% of all women will have VVC
infection during their lifetimes, typically during
their childbearing years. 1’3’4 Between 40% and
50% of women who have experienced episode of
VVC are likely to have at least recurrence, and
approximately 5% will have repeated episodes of
the disorder.
Of particular concern to physicians and other
health care professionals is the fact that the number
of prescriptions written in the United States to treat
yeast infections has almost doubled between 1980
and 1990, reaching 13 million. Statistical data
derived from patients treated at genitourinary med-
icine centers in the United Kingdom indicate a
similarly sharp increase, from 118/100,000 to 200/
100,000 patients during the last decade. More-
over, although the causative organism in 85-90%
of all cases of VVC is Candida albicans, some evi-
dence suggests that the proportion of non-albicans
Candida infections, including those caused by C.
(Torulopsis) glabrata, C. tropicalis, and C. krusei, is
rising substantially. 2’5 Traditional imidazole treat-
ment regimens have often shown less efficacy
against those species than against most of the ap-
proximately 200 known pathogenic strains of C.
albicans.
1,6,7
Amid these causes for concern, however, posi-
tive developments are the number of therapeutic
agents and range of treatment options available for
the management of VVC. Most women with acute
VVC can be treated with short-term regimens that
are likely to enhance compliance and thus minimize
the risk of treatment failure. 2’8’9 Newer triazole
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TABLE I. Drug formulations and doses commonly
used to treat VVC
a
Agent Formulation Dose
Nystatin
Clotrimazole
Miconazole
Tioconazole
Econazole
Terconazole
100,000 U vaginal tablet 100,000 U x 14 days
1% cream 5 g x 7-14 days
100 mg vaginal tablet 100 mg 7 days
100 mg vaginal tablet 200 mg 3 days
500 mg vaginal tablet 500 mg x dose
2% cream 5 g x 7 days
100 mg vaginal 100 mg 7 days
suppository
200 mg vaginal 200 mg x 3 days
suppository
1,200 mg vaginal 1,200 mg x dose
suppository
2% cream 5 g x 3 days
6.5% cream 5 g dose
150 mg vaginal tablet 150 mg 3 days
0.4% cream 5 g x 7 days
0.8% cream 5 g x 3 days
80 mg vaginal 80 mg x 3 days
suppository
Ketoconazole 200 mg oral tablet
Fluconazole 150 mg oral capsule
Itraconazole 100 mg oral capsule
400 mg x 5 days
3z
150 mg dose2s
200 mg x 3 days
4
aAdapted in part from Sobel.
formulations provide a broader spectrum of activ-
ity against non-albicans species, thereby suggesting
the possibility of better cure rates and less recurrent
disease. One decision for the physician, given this
diversity of options, is whether to prescribe a topi-
cal or an oral agent for the patient with VVC.
This review discusses the potential benefits and
liabilities of topical vs. systemic (oral) drug ther-
apy, taking into account such factors as efficacy in
acute and recurrent VVC (RVVC), potential for the
development of resistance, pathogen selection or
shift, VVC during pregnancy, potential for drug
interactions, safety profiles, and patient acceptance.
Table summarizes the formulations and dosages
of those agents that are commonly used to treat
VVC.
TREATMENT OF TOPICAL INFECTIONS
WITH TOPICAL PREPARATIONS
As a rule, it is preferable to treat topical disorders
with topical therapy. It is always advisable to in-
volve the smallest possible number of body systems
in the pharmacotherapeutic process. Even with the
use of a systemic agent that has a good safety pro-
file, concern about the development of potentially
serious adverse effects remains. In an era of fiscal
constraint, when the effective use of physician time
and the reduction of patient costs are regarded as
essential, the unnecessary monitoring of patients
for untoward effects of systemic therapy and the
possible need for additional physician visits are dif-
ficult to defend.
Concern about adverse.effects is compounded
when therapy focuses on women of childbearing
age whose acute or recurrent disorder may be an
unrecognized sign of pregnancy. Whether or not
preclinical investigations and existing data from
human populations have suggested that a given sys-
temic agent has the potential for teratogenesis, un-
less the absence of pregnancy is confirmed, the
prudent course is to treat the patient who could be
pregnant with a topical agent that has a well-estab-
lished reproductive health profile.
Similarly, the risk of potentially serious drug-
drug interactions always remains when a systemic
drug is used in lieu of a topical agent. This risk is
significantly increased when a systemic agent is to
be used primarily in a population whose members
are known to make extensive use of an interacting
class of drugs, i.e., oral contraceptives. Even when
the physician clearly delineates the implications of
drug-drug interactions to a patient and explicitly
questions her about current use of potentially inter-
acting agents, full disclosure by the patient cannot
be guaranteed.
Many studies have shown that good compliance
is unlikely to be achieved unless the patient regards
the presenting problem as a severe disorder. De-
spite VVC’s potential seriousness, women tend to
view it as a nuisance or an inconvenience rather
than a major health problem. Thus, it cannot be
assumed that patients who use a systemic agent will
refrain from the concurrent use of potentially inter-
acting drugs or modify their behaviors to minimize
the risks of drug-drug interactions.
EFFICACY IN ACUTE VVC
In immunocompetent patients with acute VVC, the
overall clinical and mycological cure rate is ex-
1,10 tremely high with both topical and oral agents.
The forms of topical antimycotic drugs include
creams, lotions, vaginal tablets, and suppositories.
There are no data that the formulation of a topical
agent influences its clinical efficacy or that the ma-
jority of women prefer a particular form of local
administration. With nystatin, the average myco-
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TABLE 2. Risk factors for VVC’3
Predisposing conditions
Pregnancy, especially in the 3rd trimester
Diabetes mellitus that is poorly controlled
Cushing’s disease
Addison’s disease
Hypo- or hyperthyroidism
Debilitating disease, e.g., leukemia, severe vitamin deficiency
AIDS or HIV infection
Vaginal trauma
Predisposing practices
Use of high-estrogen oral contraceptives
Use of antibiotics, especially tetracycline, ampicillin, and
cephalosporins
Use of therapies that compromise the immune system,
including hormones, cytotoxic agents, immunosuppressive
drugs, and radiotherapy
Frequent, traumatic sexual intercourse
Wearing of tight clothing or nylon underwear
Use of intrauterine contraceptive devices
Ingestion of a large amount of candy
logical cure rate is generally considered to range
from 75% to 80%, while it is estimated to be some-
what higher, from 85% to 90%, with the azole
derivatives.
1,3 Because of its broader spectrum of
activity, the triazole terconazole has shown excel-
lent efficacy against a wide range of pathogenic
fungi. 3’8
EFFICACY IN RVVC
RVVC, the occurrence of at least 4 mycologically
proven symptomatic episodes of VVC in year,
occurs in approximately 5% of patients with VVC.
11
Although it occurs at extremely high rates among
immunocompromised women, including approxi-
mately 24% of human immunodeficiency virus
(HIV)-infected patients,
12 it is also found in women
who have none of the risk factors generally associ-
ated with VVC (Table 2).’’ The cause ofRVVC
has not been determined, but several explanations
have been proposed.
RVVC has often been attributed to the existence
of an intestinal reservoir of Candida that acts as a
source of reinfection.2’ However, while it is true
that some patients with RVVC demonstrate rectal
colonization by Candida species, such colonization
has also been found in approximately 40% of as-
ymptomatic women. Furthermore, biotyping of
vaginal and rectal cultures simultaneously obtained
from patients with RVVC has often shown a low
concordance between cultures. A longitudinal study
ofwomen with RVVC who were receiving ketocon-
azole therapy showed that VVC sometimes recurred
when rectal cultures were negative for Candida spe-
cies. In addition, treatment with nystatin, which
reduces intestinal yeast carriage, has failed to pre-
vent symptomatic RVVC. Although the clinical rel-
evance of existing Candida reservoirs remains open
to investigation, systemic, oral therapy may be used
as an effective means of destroying these reser-
voirs.
10,4,15
Most patients with RVVC require long-term
maintenance regimens with mycosuppressive pro-
phylaxis. Extended therapy with topical clotrima-
zole or miconazole or with oral ketoconazole has
been shown to significantly reduce the frequency of
RVVC for the duration of treatment, l Neverthe-
less, approximately 50% of patients experience a
relapse within several months after treatment
ends. ’ll Although some investigators have sug-
gested that oral therapy is more likely than vaginal
therapy to promote the necessary level of patient
compliance during long-term treatment, ’9 others
have argued that the greater risk of systemic toxic-
ity associated with oral agents points in favor of
topical therapy for RVVC.
16 Oral therapy has the
potential to increase the amount of physician time
devoted to patient monitoring and to increase pa-
tient expenses associated with physician visits and
laboratory tests.
RESISTANCE AND PATHOGEN SHIFT
Some controversy exists as to whether the trend
toward shorter courses of therapy for acute VVC
and the use of long-term maintenance regimens in
RVVC have led to the selection of more resistant
strains of Candida species, such as C. tropicalis, C.
krusei, and C. glabrata (formerly Torulopsis gla-
brata). 1’2 It has been argued that, although C.
albicans remains the most common cause of VVC,
other, more resistant species are gradually assum-
ing a more prominent role. In examining the re-
sults of 9 studies conducted in the 1970s, Horowitz
et al. 2’5 found that the prevalence of non-albicans
species approximated 9.9%. By the 1980s, 7 stud-
ies revealed a non-albicans prevalence of 21.3%.
During that period, the incidence of C. glabrata
was found to have increased from 4.6% to 6.7%,
while that of C. tropicalis rose from 1.3% to 8.2%.
Although the phenomenon of pathogen shift among
yeasts has not been definitively proven,
11 most data
seem to point in that direction.
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Resistance to Topical Agents
Both in vivo and in vitro studies have demonstrated
the lack of development of resistance to topical
antifungal agents.
8 One barrier to resistance may
be the high drug concentration attained at the site of
infection. This is especially true of the azole deriv-
atives, which act on multiple targets on the plasma
membrane and within the yeast cell. The only avail-
able topical triazole, terconazole, has the added
benefit ofa broad spectrum of activity against many
non-albicans Candida species, which may prevent
3,8 selection of" more resistant yeasts.
Resistance to Oral Agents
Among the 3 oral azole antifungal agents, the fre-
quency with which resistance has been described in
a clinical setting differs considerably.
12,17 Flucon-
azole has been implicated in emergent resistance
more frequently than ketoconazole, and ketocona-
zole more often than itraconazole. Although most
reported cases of resistance have involved long-
term administration to immunocompromised pa-
tients with sexually transmitted diseases or neutro-
penia, the development of resistance may also have
some correlation in the treatment of VVC. For
example, in patients with acquired immune defi-
ciency syndrome (AIDS) and neutropenia and those
receiving treatment in intensive care units, C. gla-
brata and C. krusei are frequently cited as emergent
colonizing flora during frequent or sustained flu-
conazole therapy. Those species have also been as-
sociated with treatment failures in patients with
disseminated infections and mucosal Candida infec-
tions. Odds
17 observes that, although most of these
treatment failures are probably related to the lim-
ited susceptibility of C. glabrata and C. krusei to
fluconazole, the development of secondary resis-
tance by C. glabrata strains has also been described.
Del Palacio
18 has observed that, although empiric
prophylactic use of fluconazole in neutropenic pa-
tients has led to a decreased frequency of C. albicans
and C. tropicalis infections, such therapy seems to
encourage the emergence of less common strains
with a native resistance to fluconazole, including C.
krusei, C. glabrata, C. lambica, and C. lusitaniae.
MANAGEMENT OF VVC DURING
PREGNANCY
During pregnancy, the vagina is particularly sus-
ceptible to Candida infection because of a higher
glycogen content, increased estrogen levels, and the
presence of other reproductive hormones. Can-
dida strains can be found in vaginal cultures of
10-20% of pregnant women, and the incidence of
colonization has been reported to be even higher
during the 3rd trimester of pregnancy.
10 The inci-
dence of symptomatic VVC is twice as high as it is
in the nonpregnant state. Treatment ofVVC during
pregnancy is indicated not only to alleviate the wom-
an’s symptoms, but also to protect the fetus from
potentially fatal Candida sepsis.
10
Although clinical response during pregnancy
tends to be slower and recurrences are more fre-
quent, most topical antifungal agents are effective,
especially when administered for 1-2 weeks. Al-
though little systemic absorption of topical antifun-
gal drugs occurs, the risk to the fetus during the st
trimester of pregnancy should be weighed against
the benefit derived by the mother. Many practi-
tioners consider treatment with topical agents to be
relatively safe during the 2nd and 3rd trimesters.
9
Administration of oral ketoconazole, fluconazole,
and itraconazole during pregnancy is not recom-
mended.
19,20 Because the development ofVVC may
be an early sign of pregnancy and since it is not
always feasible to administer a pregnancy test to
each woman of childbearing potential who presents
to the physician with acute VVC, the safest course is
the use of a topical agent for first-line therapy.
In addition, fluconazole, itraconazole, and prob-
ably ketoconazole are excreted in breast milk.
Therefore, the use of systemic agents should be
limited to those women who choose not to breast-
feed. Alternately, topical therapy can be used dur-
ing this time.
POTENTIAL FOR DRUG INTERACTIONS
Although significant drug interactions have not
been associated with the use of topical antifungal
agents, the potential for such drug interactions ex-
ists with oral therapy.
21 Table 3 lists those agents
that are associated with the greatest risk for signifi-
cant interaction with ketoconazole, fluconazole, and
itraconazole.
Among the drug interactions associated with ad-
ministration of the oral azoles, 2 are of particular
concern because of the characteristics of the patients
who typically present with VVC. It is ironic that,
although VVC generally occurs in women of child-
bearing age and is especially common among those
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TABLE 3. Agents with the greatest potential for
interaction with the oral azoles27-29
Antacids Isoniazid
Anticholinergics Loratadine
Anticoagulants Methylprednisolone
Astemizole Oral contraceptives
Cimetidine Phenytoin
Cyclosporine Potassium
Digoxin Rifampin
Diuretics Sulfonylureas
Hz antagonists Terfenadine
Hypoglycemics
who take estrogen-containing oral contraceptives,
the oral azoles have the potential to interact with
oral contraceptives.
22 As noted previously, the oral
azoles are not recommended for young women who
are not using a reliable method of birth control.
10
Another area of special concern is that of diabetic
patients. Although women with diabetes are at
heightened risk for the development of VVC, 1’13
the potential for interaction exists when oral azoles
are concurrently taken with oral hypoglycemics.
23
The fact that a diabetic woman has developed symp-
tomatic VVC suggests that her blood glucose levels
are poorly controlled, and treatment of VVC with
an oral azole can further compromise that control.
In view of the increasing use of the nonsedating
antihistamines terfenadine and astemizole, physi-
cians must advise patients of" the severe cardiovas-
cular adverse effects, including prolonged QT in-
tervals, that may arise when oral azoles are
coadministered with those agents,
z3 Conversely,
patients should be cautioned that concomitant use of
He antagonists can impair the efficacy of the oral
azoles.
The extent to which drug interactions with oral
azoles may occur in actual clinical practice was
suggested by a cross-sectional observational study
conducted over a 12-week period at an urban hospi-
tal in Australia.
23 Of 7 6 patients receiving flucon-
azole, 3 5 had been prescribed potentially interact-
ing drugs and 9 of those patients were judged to
have experienced 10 possible adverse interactions.
In patient who received concomitant cyclosporine
and fluconazole, the cyclosporine plasma concen-
tration rose from 7 53 ng/ml to 1,543 ng/ml after 6
days of combination therapy. Potential adverse re-
actions also occurred in patients receiving flucona-
zole in conjunction with the following drugs: war-
farin (2 of 4 patients), theophylline (1 of 2),
phenytoin (3 of 9), rifabutin (2 of 4), and rifampin
(1 orS).
The risk of potentially serious drug interactions
may place a significant burden on the physician
who elects to prescribe one of the oral azoles as
first-line therapy for VVC. Patients must be ques-
tioned carefully about the medications they are cur-
rently receiving, and the possibility of an inaccu-
rate self-report always exists. The physician who
consciously prescribes an oral azole for a woman
who is also receiving a potentially interacting drug
must expend significant effort in monitoring the
patient. Similarly, the patient may be required to
bear the economic burden of additional physician
visits and laboratory tests to monitor plasma con-
centrations or other relevant parameters.
ADVERSE EFFECT PROFILES
Overall, a low incidence of adverse effects has been
reported for both topical and oral antifungal agents
used to treat VVC. It is noteworthy that a similar
incidence and range of adverse effects have some-
times been reported by VVC patients receiving ac-
tive drug and placebo.
14
Adverse Reactions and Topical Therapy
Administration of topical azoles is associated with
few local and systemic side effects. The most com-
mon local effects, which are usually minor, are
vaginal burning, stinging, itching, irritation, and
pain; dyspareunia may also occur. 3’8’14’24’25 Over-
all, approximately 7% of women using azole anti-
fungal cream preparations have reported some de-
gree of" treatment-related vaginal discomfort.
9
Additional side effects reported with topical agents
include increased frequency of urination, pelvic
cramps, dysmenorrhea, paresthesia, rhinorrhea,
headache, fever, and chills. 3’8’15’22’24’25
Adverse Effects Associated With Ketoconazole
The most common adverse effects reported with
ketoconazole are mild gastrointestinal disorders, in-
cluding nausea, vomiting, and abdominal pain;
these have been reported in approximately 10% of
patients receiving the drug. At doses greater than
400 mg/day, some cases of androgen biosynthesis
blockade have been described,z A few cases of
anaphylaxis have also been reported. Although he-
patotoxicity was initially estimated to occur in
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1/10,000 patients treated, the reported incidence
has more recently fallen to 1/70,000. Part of this
decrease can probably be attributed to a tendency
for physicians to prescribe shorter courses of ther-
apy. The incidence of hepatic reactions appears to
be higher in women; patients being treated for
onychomycosis; patients with preexisting liver dis-
ease or alcoholism; patients who receive more than
2 weeks oftherapy or who have previously received
16 griseofulvin; and those over the age of 50 years.
Adverse Effects Associated With Fluconazole
Mild gastrointestinal symptoms, including nausea,
vomiting, abdominal pain, and diarrhea, have been
reported in approximately 5% of patients receiving
fluconazole for VVC. 4’18’25’26 Headache, dizzi-
ness, dry mouth, rash, and dry skin have also been
reported with some regularity. Approximately
5.1% of patients treated with fluconazole for super-
ficial infection show abnormal liver function test
results, as opposed to 3.7% of patients receiving
topical treatments with clotrimazole.
2
Although severe toxic epidermal necrolysis has
been reported in a small number of patients treated
with fluconazole, those patients were typicallyAIDS
patients who had been receiving concomitant drug
therapy for tuberculosis. Thus, a clear association
between fluconazole and epidermal necrolysis has
not been established,z One case ofthrombocytope-
nia has also been reported. A case of angioedema
with buccal ulceration was reported in a 21-year-
old woman who had taken the 6th of twice-monthly
prophylactic doses of 15 0 mg fluconazole that had
been prescribed for RVVC of 3 years duration.
27
The case of a healthy 22-year-old woman who
experienced an anaphylactic reaction a few minutes
after administration of 150 mg of oral fluconazole
as treatment for VVC has been reported.
28 Although
the patient had had no previous contact with flucon-
azole, she had been treated with ketoconazole 2.5
years before the reported reaction. She had also
received vaginal metronidazole year before and
oral metronidazole week before the event. Results
of a prick test with fluconazole solution were posi-
tive at a 1:10 dilution. It appears likely that the
patient experienced an allergic reaction to flucona-
zole that may have been caused by cross-sensitiza-
tion to ketoconazole or metronidazole.
Adverse Effects Associated With Itraconazole
The overall incidence of minor adverse effects re-
ported with itraconazole has been estimated to range
from 7% to 10%.
20 Most have consisted of mild
gastrointestinal disturbances.
13 Malaise, headache,
dizziness, transient faintness, psychiatric effects,
fever, hypertension, and edema have also been re-
ported.
14,16,22 Hypokalemia has been associated
with high-dose therapy. Although a few cases of
reversible peripheral neuropathy have been re-
ported, a firm association with itraconazole has not
been established,z The incidence of hepatic reac-
tions, including hepatitis, is approximately 6 in
almost 5 million treatments. A low frequency
(0.9%) of reversible changes in liver function tests
has also been reported.
13,14,20
PATIENT ACCEPTANCE
Since acute VVC in immunocompetent patients usu-
ally responds to antifungal treatment, it has often
been argued that many apparent treatment failures
are actually the results of poor patient compli-
ance. 9’15’24 Because studies have repeatedly shown
that key factors in achieving compliance are a brief,
uncomplicated dosage regimen and the patient’s sat-
isfaction with the nature of the treatment, patient
preferences are important considerations in evalu-
ating treatment alternatives. Some studies have
indicated that when efficacy is comparable, women
tend to prefer oral to topical therapy.29’ It has
also been suggested, however, that application of a
topical agent to the affected area may confer more
rapid symptomatic relief for some patients.
Whether this benefit is real or only perceptual, the
physician may wish to consider concomitant ther-
apy with a topical drug when using a systemic
antifungal.
CONCLUSIONS
In light of the comparable levels of efficacy re-
ported for topical and oral agents in the treatment
ofVVC and RVVC, major criteria for determining
whether to prescribe a local or systemic agent in-
clude issues related to drug resistance and pathogen
shift, safety in pregnancy, drug interactions, ad-
verse effects, and patient acceptance.
Patients who are pregnant or suspected to be
pregnant and women of childbearing age who are
not using a reliable method of contraception should
receive topical therapy. Women who are breast-
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feeding or receiving one or more drugs with the
potential to interact with the oral azoles should also
be treated topically, as should those with a history
of adverse reactions to the azoles or with significant
liver impairment.
Whichever form oftherapy is ultimately chosen,
the shortest feasible course of treatment is advis-
able. The potential for resistance and pathogen shift
with oral drugs argues for the use of broad-spec-
trum topical therapy.
Because the potential risks and disadvantages asso-
ciated with oral therapy tend to outweigh the benefits,
treatment with topical agents should be regarded as
the method ofchoice for patients with VVC, although
oral agents may have a place in the treatment ofRVVC
or in those patients in whom the benefits may out-
weigh any possible adverse reactions.
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